Skip to content

The Antidepressive Effect of rTMS as add-on to ECT

The Antidepressant Efficacy of Repetitive Transcranial Magnetic Stimulation ( rTMS) as add-on to Electroconvulsive Therapy (ECT). A Double Blind Randomized Controlled Trial.

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02123485
Acronym
TMS
Enrollment
35
Registered
2014-04-25
Start date
2015-04-01
Completion date
2019-07-01
Last updated
2021-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression,, ECT,, rTMS,, Right prefrontal,, antidepressive efficacy

Brief summary

The aim of the present study is to investigate in which degree low frequency right prefrontal rTMS used ad add-on may potentiate the antidepressant effect of unilateral ECT and accelerate remission . To investigate the correlation between blood concentration of specific inflammation makers and change in depressive symptoms during treatment

Detailed description

ECT is a well-established and effective method for the treatment of severe depression. During the last decades, rTMS has appeared as a potential new non-invasive antidepressant method, which may be a potential alternative to ECT due to fewer side effects. Both methods expose the brain to an electric current. But while ECT is associated with global cerebral stimulation elicited by an epileptic seizure, rTMS implies non-convulsive focal stimulation through a time varying magnetic field. Thus, the antidepressant effect of rTMS does not depend on seizure activity and consequently requires no anesthesia. In addition, rTMS seems not to be associated with cognitive disturbances. Previous research indicates that the antidepressant effect of rTMS is associated with specific stimulation of the dorsolateral prefrontal cortex. The majority of clinically controlled studies have used high frequency stimulation of the left frontal cortex (1-4). Few have used right prefrontal low frequency rTMS, which has less side effects, such as local discomfort and a lower risk of releasing epileptic seizures, than high frequency stimulation (5-10). Both models have been used with varying results. Meta-analysis of the antidepressant effect of rTMS (11,x) have found a modest, statistically significant antidepressant effect but generally definite conclusions on the antidepressant effect of rTMS has been difficult to draw, probably because of small and selected study populations, varying ways of stimulation and other confounding factors in the clinical setting. The important clinical question of whether rTMS may substitute ECT in the treatment of depression has almost exclusively been elucidated in studies using high frequency stimulation of the left frontal cortex. Some of these suggest that the effectiveness of rTMS is equal to that of ECT in non-delusional patients (12-19). However, a recent investigation has compared the antidepressant efficacy and side effects of right prefrontal low frequency rTMS with ECT. In this study the mean Hamilton total 17-item (HAM-D score) scores were reduced significantly over time in both groups (ECT: p\<0.001, rTMS: p\<0.001); but ECT was more effective than rTMS on a short term after 3 weeks of treatment. The outcome did not point to right frontal low frequency rTMS as a first line substitute for ECT, but it might have place in the treatment of depression as add on to other types of treatment. ECT is normally administered 3 times a week for 3-4 weeks. Daily treatment sessions might accelerate remission, but is impossible because of cognitive side effects. However, rTMS seems not to be associated with reduction in cognitive performance and might potentiate the antidepressant efficacy of ECT. Therefore the investigators have found it clinical interesting to investigate in which degree low frequency right prefrontal rTMS used ad add-on may potentiate the antidepressant effect of unilateral ECT and accelerate remission . In addition we want to investigate te correlation between change in depressive symptoms and -blood concentration of specific inflammation CNS- makers

Interventions

DEVICELow frequency (1 hz) rTMS, as add-on to ECT

Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.

DEVICESham-rTMS

Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Patients admitted to the Psychiatric Hospital of Aarhus * Patients referred for ECT * Age 18-80 years * Moderate or severely depressed patients (ICD-10(DSM-IV) * HAM-D score (17-item) ≥20 and/or Ham-D subscale ≥10.

Exclusion criteria

* Organic brain disease * Epilepsy or disposition to epilepsy * Metallic objects in chest or brain * Cardiac pacemaker * Somatic diseases associated with brain dysfunction * Pregnancy * Severe agitation or delirium * Alcohol or drug dependence (ICD-10) * Use of coercive measures * The patient does not wish to participate

Design outcomes

Primary

MeasureTime frameDescription
Remission7 weeksThe Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcomeRemission is defined by a Hamilton 17-item total score \< 8.

Secondary

MeasureTime frameDescription
Response7 weeksThe Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcome. Response is defined by a reduction in the Hamilton 17 item score of \>= 50%

Countries

Denmark

Participant flow

Participants by arm

ArmCount
Low Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)
Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week Low frequency (1 hz) rTMS, as add-on to ECT: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
18
Sham-rTMS
Sham right prefrontal rTMS 2 times a week Sham-rTMS: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
17
Total35

Baseline characteristics

CharacteristicLow Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)Sham-rTMSTotal
Age, Continuous50 years47 years49 years
Antidepressant drug treatment18 Participants16 Participants34 Participants
Hamilton depression scale score
Hamilton depression rating scale (17-item)
24 units on a scale26 units on a scale25 units on a scale
Hamilton depression scale score
Hamilton depression rating scale (6-item)
13 units on a scale13 units on a scale13 units on a scale
Hamilton depression scale score
Major Depression inventory
45 units on a scale41 units on a scale43 units on a scale
number of patients with bipolar depressive1 Participants6 Participants7 Participants
number of patients with melancholic depression16 Participants13 Participants29 Participants
number of patients with psychotic depression2 Participants3 Participants5 Participants
Number of patients with Severe depression15 Participants17 Participants32 Participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Denmark
18 participants17 participants35 participants
Sex: Female, Male
Female
13 Participants12 Participants25 Participants
Sex: Female, Male
Male
5 Participants5 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 170 / 17
other
Total, other adverse events
4 / 123 / 14
serious
Total, serious adverse events
1 / 120 / 14

Outcome results

Primary

Remission

The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcomeRemission is defined by a Hamilton 17-item total score \< 8.

Time frame: 7 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Low Frequency rTMSRemission7 Participants
Sham-rTMSRemission10 Participants
p-value: 0.3Chi-squared
Secondary

Response

The Hamilton (17 -item) Rating Scale for Depression is a clinician-administered assessement scale, that contains 17 items pertaining to symptoms of depression experienced over the past week. The total range is 0-52.Higher scores mean a worse outcome. Response is defined by a reduction in the Hamilton 17 item score of \>= 50%

Time frame: 7 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Low Frequency rTMSResponse11 Participants
Sham-rTMSResponse13 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026